ITGB1 and cancer: The expression levels of cancer stem cell markers CD24 and CD29 were lower in doxorubicin-treated mice than in controls (Figure 6C), with lower expression in mice treated with doxorubicin plus FO/Se supplements than with doxorubicin alone.